PARADIGM-HF试验:射血分数降低心衰患者体格检查淤血体征的预后价值
该研究基于PARADIGM-HF试验中8380例射血分数降低心衰患者,分析基线及随访中淤血体征(颈静脉怒张、水肿、啰音、第三心音)与临床结局及生活质量的关系。在校正利钠肽、MAGGIC评分和NYHA分级后,时间更新的淤血体征数量仍与所有结局独立相关(P<0.001)。沙库巴曲/缬沙坦较依那普利更显著改善淤血(P=0.011),且每减少1个体征,KCCQ总分独立改善5.1分(95%CI 4.7-5.5)。
要点
- 心衰患者基线淤血体征越重,预后越差,独立于利钠肽和风险评分。
- 沙库巴曲/缬沙坦较依那普利更有效改善淤血体征。
- 减少淤血体征与生活质量改善及心血管事件减少独立相关。
核心结论
- 在射血分数降低心衰患者中,体格检查淤血体征提供独立于症状、利钠肽和MAGGIC评分的预后价值。
- 沙库巴曲/缬沙坦较依那普利更显著改善淤血。
- 减少门诊淤血与改善生活质量和减少心血管事件(包括死亡)独立相关。
研究设计与样本
- 分析PARADIGM-HF试验中基线有体格检查数据的8380例射血分数降低心衰患者。
- 采用时间更新多变量校正Cox回归分析淤血体征数量与结局的关联。
主要发现
- 基线时0、1、2、3+个体征的患者比例分别为70%、21%、7%、2%。
- 时间更新淤血体征数量与主要结局、其各组分及全因死亡均相关(P<0.001)。
- 沙库巴曲/缬沙坦降低主要结局风险与基线淤血体征无关(交互P=0.16),且改善淤血程度优于依那普利(P=0.011)。
- 每减少1个体征,KCCQ总分独立改善5.1分(95%CI 4.7-5.5)。
- 淤血变化强烈预测结局,即使校正基线淤血后仍显著(P<0.001)。
关键数值与推荐
- 淤血体征包括颈静脉怒张、水肿、啰音和第三心音。
- 主要结局为心血管死亡或心衰住院。
- 生活质量采用KCCQ总体总结评分评估。
临床怎么用
- 心衰管理中应重视体格检查淤血体征的动态评估。
- 沙库巴曲/缬沙坦可优先用于希望改善淤血的患者。
- 减少淤血体征可作为改善生活质量和预后的治疗目标。
局限性
- 研究基于PARADIGM-HF试验人群,结果可能不适用于其他心衰人群。
- 淤血体征评估可能存在观察者间差异。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The contemporary prognostic value of the physical examination- beyond traditional risk factors including natriuretic peptides, risk scores, and symptoms-in heart failure (HF) with reduced ejection fraction is unknown. We aimed to determine the association between physical signs of congestion at baseline and during study follow-up with quality of life and clinical outcomes and to assess the treatment effects of sacubitril/valsartan on congestion. METHODS: We analyzed participants from PARADIGM-HF (Prospective Comparison of Angiotensin Receptor-Neprilysin Inhibitor With Angiotensin Converting Enzyme Inhibitor to Determine Impact on Global Mortality and Morbidity in HF) with an available physical examination at baseline. We examined the association of the number of signs of congestion (jugular venous distention, edema, rales, and third heart sound) with the primary outcome (cardiovascular death or HF hospitalization), its individual components, and all-cause mortality using time-updated, multivariable-adjusted Cox regression. We further evaluated whether sacubitril/valsartan reduced congestion during follow-up and whether improvement in congestion is related to changes in clinical outcomes and quality of life, assessed by Kansas City Cardiomyopathy Questionnaire overall summary scores. RESULTS: Among 8380 participants, 0, 1, 2, and 3+ signs of congestion were present in 70%, 21%, 7%, and 2% of patients, respectively. Patients with baseline congestion were older, more often female, had higher MAGGIC risk scores (Meta-Analysis Global Group in Chronic Heart Failure) and lower Kansas City Cardiomyopathy Questionnaire overall summary scores (P<0.05). After adjusting for baseline natriuretic peptides, time-updated Meta-Analysis Global Group in Chronic Heart Failure score, and time-updated New York Heart Association class, increasing time-updated congestion was associated with all outcomes (P<0.001). Sacubitril/valsartan reduced the risk of the primary outcome irrespective of clinical signs of congestion at baseline (P=0.16 for interaction), and treatment with the drug improved congestion to a greater extent than did enalapril (P=0.011). Each 1-sign reduction was independently associated with a 5.1 (95% CI, 4.7-5.5) point improvement in Kansas City Cardiomyopathy Questionnaire overall summary scores. Change in congestion strongly predicted outcomes even after adjusting for baseline congestion (P<0.001). CONCLUSIONS: In HF with reduced ejection fraction, the physical exam continues to provide significant independent prognostic value even beyond symptoms, natriuretic peptides, and Meta-Analysis Global Group in Chronic Heart Failure risk score. Sacubitril/valsartan improved congestion to a greater extent than did enalapril. Reducing congestion in the outpatient setting is independently associated with improved quality of life and reduced cardiovascular events, including mortality. CLINICAL TRIAL REGISTRATION: https://www.clinicaltrials.gov. Unique identifier: NCT01035255.
引用
- Selvaraj S, Claggett B, Pozzi A, et al. Prognostic Implications of Congestion on Physical Examination Among Contemporary Patients With Heart Failure and Reduced Ejection Fraction: PARADIGM-HF. Circulation. 2019. PMID: 31510768. doi:10.1161/CIRCULATIONAHA.119.039920
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。